CLOSE

Specials

  • March
  • June
  • September
  • Bioanalytical Services
  • Life Science Analytics
  • Life Science Compliance
  • Bioanalytical Services APAC
  • APAC
  • Europe

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
APAC
  • Home
  • News
  • Contributors
  • Magazine
  • Conferences
  • Newsletter
  • About

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Managing Risk and Minimizing the...

Timothy Korwan, Director, New Product Development...

In Personalized Medicine Logistics,...

Scott Ohanesian, Senior VP Commercial Operations,...

Unlock the Power of Data

Jijo James, M.D., M.P.H., Chief Medical Officer,...

A Growing Reliance on Outsourcing Warrants...

Greg Aimi, Vice President, Team Manager, Supply...

AI Can Improve Patient Outcomes, but will...

Ryan Billings, MS, MBA, Executive Director, Digital...

Are Wearables and Sensors the Key to...

Marie McCarthy, Director, Product Innovation, ICON plc

What is Next After Serialisation?

Ulrike Kreysa, Senior Vice-President of Healthcare, GS1

The Challenge of Complex Biologics...

Ron Guido, VP, Regulatory Affairs, IRX Therapeutics

Managing Risk and Minimizing the...

Timothy Korwan, Director, New Product Development...

In Personalized Medicine Logistics,...

Scott Ohanesian, Senior VP Commercial Operations,...

Unlock the Power of Data

Jijo James, M.D., M.P.H., Chief Medical Officer,...

A Growing Reliance on Outsourcing Warrants...

Greg Aimi, Vice President, Team Manager, Supply...

AI Can Improve Patient Outcomes, but will...

Ryan Billings, MS, MBA, Executive Director, Digital...

Are Wearables and Sensors the Key to...

Marie McCarthy, Director, Product Innovation, ICON plc

What is Next After Serialisation?

Ulrike Kreysa, Senior Vice-President of Healthcare, GS1

The Challenge of Complex Biologics...

Ron Guido, VP, Regulatory Affairs, IRX Therapeutics

Life Sciences: Macro View

By Rajeev Nair, CIO, J. Knipper & Company
Tweet

In Pharma, as R&D budgets come under heavy pressure, industry continues to be fraught with M&A aimed at product and patent acquisition. So integration continues to be a key concern to gain efficiencies and develop a single, unified compliance and regulatory layer; however, gone are the days where you could afford a multi-year rigid, monolithic ERP rollout; not just because of prohibitive costs, but also time for value recognition.


Healthcare market is going through rapid changes given new regulations – so pharma companies are extremely hungry for market intelligence - product efficacy, patient compliance, market penetration & reimbursement related - Analytics, not just the ability to integrate internal operational and sales data with market data, both structured & unstructured, but also be able to generate predictive behaviors becomes key. This means that the life sciences industry cannot afford to rely on single platforms or solution (providers) to meet the changing market needs. The need to seamlessly partner with various providers, both established and disruptive, who have USPs in niche areas becomes key.


Technology Implications: Need a New Model


The above macro factors point to a key technology theme – agility


• M&A - Agility to integrate up and down the value chain and with new acquired entities


• Analytics - Agility to partner with external data providers and integrate with internal operational data


• Changing Market needs - Agility to build flexible integration points that allow the enterprise to quickly partner with upcoming and disruptive service providers for niche needs


The traditional landscape that is riddled with monolithic applications like traditional ERP, CRM, BI systems don’t allow the flexibility and agility that today’s needs demand. Configurable services with flexible integration points become important as instantaneous integration becomes critical; in addition, for a service provider who provides end to end solutions like JKC, the ability to provide a platform where clients could pick and choose specific elements of the service portfolio to be integrated with their operations.


However, at the same time, traditional values don’t go away – predictability, compliance needs, efficiency etc. These needs almost seem like the antithesis of agility and flexibility.


More flexible and agile architectures that have faster integration platforms and configurable services become vital to survive and excel in this landscape – an example is micro-services architecture. In a micro-services architecture, software applications are developed as a suite of small, independently deployable modular services, in which each service serves a unique purpose and communicates through a clearly defined, light weight mechanism. Such an architecture has several advantages:


•Agility breeds scalability – a highly popular, in demand service can be deployed in multiple, more powerful servers to meet an increased need. This works really well with both in-house and IaaS and PaaS (cloud) landscapes where metered boosting of performance at a service level will be possible. Hard to achieve that through traditional IT deployment models


• Agility enables technology/platform agnosticism: Ability to choose specific technology for each service – this becomes vital while responding to specific providers in the market driving technology platform decisions


• Agility enables compliance – since each service serves a unique purpose and can be changed independent of each other, testing becomes easier due to higher predictability, and it drives compliance costs lower


• Agility breeds predictability and reduces risk: Contrary to large monolithic applications, since each service exists independent of each other, the potential of failure of one service doesn’t impact any others


• Agility enables quick integration, thus faster results: Loosely defined, light weight integration allows faster integration with the in-house organization’s and its providers’ and customers’ applications – this provides the agility an organization needs to have to respond to changing market needs.


Weekly Brief

loading
Towards a New World Order
> <
  • Other 2021

    Top Vendors

    Current Issue
  • Other 2020

    Top Vendors

    Current Issue

Read Also

Maintaining A Patient-Focused Community Pharmacy With Consumer Technology

Dale Danilewitz, Executive Vice President & CIO, AmerisourceBergen [NYSE:ABC]
Maintaining A Patient-Focused Community Pharmacy With Consumer Technology

Navigating Technology Transformations for CIO Success

Steve Betts, CIO, Health Care Service Corporation
Navigating Technology Transformations for CIO Success

Enhancing Rural Medicine and Healthcare

Jake Dorst, Chief Information & Innovation Officer, Tahoe Forest Hospital District
Enhancing Rural Medicine and Healthcare

Efficient Data Management in the Healthcare Space

Jim Simpson, SVP & CIO, AvMed
Efficient Data Management in the Healthcare Space
The Next Big Thing in Pharma and Life sciences industry

The Next Big Thing in Pharma and Life sciences industry

Mark Williams, VP CIO, ACI Clinical
The Changing Role of CIO in the Biopharmaceutical Industry

The Changing Role of CIO in the Biopharmaceutical Industry

Andy Newsom, CIO, CSL Behring

How Technology is Disrupting the Pharma and Life Sciences Industry

Colin Boatwright, CIO, Ironshore Pharmaceuticals Inc
How Technology is Disrupting the Pharma and Life Sciences Industry

XR in Healthcare: Simple Evolution or Amazing Revolution?

Grégory Maubon, Digital Coordinator CIO/CDO, HCS Pharma
XR in Healthcare: Simple Evolution or Amazing Revolution?
Loading...

Copyright © 2021 Life Science Review . All rights reserved. |  Subscribe follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cioviewpoint/life-sciences-macro-view-nwid-54.html